How Industry Benchmarks Can Inform CDMO Selection

By Laura McWhinney

When selecting a CDMO, biopharmaceutical sponsors will always consider timelines, cost, regulatory requirements, capacity, quality, risks, and previous experience, among other factors. While more commonly utilized as a market research tool, one company is conducting quarterly manufacturing-specific benchmark studies that ask professionals in the biopharmaceutical sphere about their experiences with CDMOs to better understand and prioritize development and manufacturing elements.

As part of the study, respondents evaluate suppliers they have worked with in the past 18 months on 23 performance metrics, which include attributes related to company strengths, capabilities, staff characteristics, services, and more. In 2022, the most important attributes varied across the four manufacturing areas (i.e., biologic API, biologic drug product, small molecule API, and small molecule drug product), but the attribute gaining in importance was shared across all four benchmarks.

Learn more about what sponsors consider to be the “Most Important” attributes in a CDMO and how the performance benchmark reports are helping make the selection process less arduous.